Working… Menu

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) (LAM-002A/NHL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02594384
Recruitment Status : Unknown
Verified August 2019 by AI Therapeutics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : November 3, 2015
Last Update Posted : August 13, 2019
Information provided by (Responsible Party):
AI Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : December 2020